ライフサイエンスコーパス: HRT

1 HRT does not directly associate with either CRY2 or PHOT

2 HRT is a powerful predictor of both CD and arrhythmic ev

3 HRT measurement variability has recently been better cha

4 HRT measurements in right eyes differed slightly in rim

5 HRT overestimated optic disc area as compared to SD-OCT.

6 HRT power increases in combination with T-wave alternans

7 HRT rim area was larger than Cirrus measurements (P < 0.

8 HRT use (versus none) was associated with higher attachm

9 HRT use at entry or during the trial was not effective i

10 HRT users were more likely to have isolated IGT (2.2 [1.

11 HRT users who develop receptor-positive early-stage dise

12 HRT VCDR and cup volume were significantly smaller than

13 HRT, GDx and OCT findings are assessed separately.

14 ion of the HRT operational software (HRT-3), HRT's ability to correctly classify glaucomatous optic n

15 women using (n = 238) or not using (n = 378) HRT were compared.

16 Abnormal HRT was a predictive marker for all the end points in he

17 The combination of abnormal HRT and T-wave alternans (5 cohorts: 1516 patients) incr

18 ch analyzed the predictive value of abnormal HRT for the defined end points.

19 ificantly different from normal discs in all HRT and OCT parameters (P<0.001).

20 d basophil histamine release test (Allerport HRT).

21 their randomized trials that estrogen alone HRT decreases the risk of breast cancer in postmenopausa

22 coding SNP (R73H) rs10490923 (P = 0.007) and HRT x ARMS2 intronic SNP rs17623531 (P = 0.019).

23 s the associations between dietary boron and HRT with lung cancer risk.

24 s pH of 6.5, temperature of 55 degrees C and HRT of 2 days, 2754 mg/L volatile fatty acids (VFAs) wer

25 indicating that temperature<60 degrees C and HRT>3 days are critical to operate these systems stably.

26 depth and HRT), dynamic control of depth and HRT was shown to increase productivity by 0.6-9.9% while

27 (constant and location-independent depth and HRT), dynamic control of depth and HRT was shown to incr

28 l thickness, pattern standard deviation, and HRT disc area, the following HRT parameters were associa

29 healthy controls with data on both diet and HRT.

30 ns between BC and both commission errors and HRT in boys, but BC was not significantly associated wit

31 rt study of the association between GORD and HRT found a statistically significant association betwee

32 ed among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (

33 ke and the joint effects of boron intake and HRT on lung cancer risk in women.

34 isk or the joint effects of boron intake and HRT use on lung cancer risk.

35 al neurogenesis was elevated in both LRT and HRT rats that underwent endurance training on a treadmil

36 iation between a diagnosis of meningioma and HRT use, with an odds ratio of 2.2 (95% CI, 1.9 to 2.6;

37 classify glaucomatous optic neuropathy, and HRT's role in monitoring disease progression.

38 from Bland-Altman plots comparing SD-OCT and HRT measurements showed suboptimal agreement between the

39 odds ratio, FDT, oculokinetic perimetry, and HRT II are promising tests.

40 Dx-VCC versus StratusOCT for global RNFL and HRT-II versus StratusOCT for global ONH topography.

41 Based on the influence of sex and HRT on the prevalence of isolated IFG and isolated IGT,

42 which a balance between Notch signaling and HRT activity determines the expression of smooth muscle

43 Resistance to TCV and HRT gene expression in HRT act1 plants was inducible by

44 l or diffuse), or a combination thereof; and HRT-based Moorfields Regression Analysis (MRA) results o

45 GDx-VCC and HRT-II showed better repeatability than StratusOCT.

46 es between 55 degrees C and 65 degrees C and HRTs between 2 and 4 days on process performance, microb

47 OCT, and GDx VCC) and neuroretinal rim area (HRT II) and SAP sensitivity expressed in decibels were d

48 deviation (r = -0.44; P = 0.005) as well as HRT linear cup-to-disc ratio (r = 0.61; P < 0.001) and s

49 Cell-based HRT (cHRT) is an alternative approach that may allow cer

50 ospective study suggests that estrogen-based HRT has limited effectiveness among women receiving tamo

51 Each baseline HRT parameter was assessed in univariate and multivariat

52 Several baseline HRT parameters, alone or in combination with baseline cl

53 balanced against the risk for flare because HRT did not significantly increase the risk for severe f

54 Furthermore, for women who first began HRT in the first 6 months of the trial compared with wom

55 trial compared with women who did not begin HRT, HRT seemed to be much more effective in controlling

56 The association between HRT and clinical periodontal measures was strongest amon

57 s study investigated the association between HRT and GORD in menopausal women using validated general

58 s evidence of a positive association between HRT use and diagnosis of meningioma, and therefore, HRT

59 g gaps in understanding the relation between HRT and breast cancer risk.

60 atusOCT measurements and are similar between HRT II and GDx VCC and these associations are generally

61 ation carriers is altered by use of post-BPO HRT.

62 Exactly half as many eyes were abnormal by HRT MRA.

63 prevalence of isolated IFG did not differ by HRT status.

64 Optic nerve head parameters measured by HRT 3 were compared between fellow eyes.

65 n in optic nerve head parameters measured by HRT 3.

66 Using combination HRT (of any duration) was associated with a substantial

67 ween PPI use and oestrogen-only and combined HRT treatment.

68 mone use (oestrogen-only, tibolone, combined HRT and progestogen) were statistically significantly as

69 a measurements were larger than AL-corrected HRT and SD-OCT measurements (P < 0.001 for both) and the

70 The AL-corrected HRT disc area and uncorrected/corrected Cirrus disc area

71 Mean keratometry-corrected HRT disc area measurements were larger than AL-corrected

72 occoides mccartyi, were operated at a 50 day HRT and fed PCE (1.12 mM) and lactate (4.3 mM).

73 on lab-scale reactors performance at 20 days HRT, shifted from neutral to positive (energy gain aroun

74 e of 37% achieved at 55 degrees C and 4 days HRT.

75 Temporally defined HRT activity may constitute a negative feedback mechanis

76 emptying the anode for 1-3 days or different HRTs.

77 Significance of change at each HRT superpixel between each follow-up and its nearest ba

78 When compared to the equivalent HRT measurements, SD-OCT-derived measures differed signi

79 To evaluate HRT effects, postmenopausal women using (n = 238) or not

80 deviation, and HRT disc area, the following HRT parameters were associated with the development of O

81 eters was 0.71 for StratusOCT-VIRA, 0.57 for HRT-II cup-to-disc area ratio, 0.51 for GDX-VCC NFI, 0.3

82 superonasal VF; logarithmic association) for HRT II; from 0.02 (temporal RNFL, nasal VF; linear assoc

83 ignificantly different from normal discs for HRT parameters, except for mean RNFL thickness and cup s

84 classification of outside normal limits for HRT and OCT or NFI >/= 56 (GDx).

85 icant inverse associations were observed for HRT (odds ratio [OR] = 0.65, 95% CI 0.48-0.90, P = 0.008

86 The strongest interactions were observed for HRT x ARMS2 coding SNP (R73H) rs10490923 (P = 0.007) and

87 nents of the widely prescribed drug used for HRT.

88 000 permuted topographic series derived from HRT images of 18 healthy eyes from Moorfields Eye Hospit

89 Rim area measurements from HRT were larger than from SD-OCT, likely a result of dif

90 In contrast, vertical C/D ratio from HRT-II, and horizontal C/D ratio from StratusOCT showed

91 and High Resolution GC x GC-TOF-MS (GC x GC HRT-4D).

92 (Di)-17 is conferred by the resistance gene HRT and a recessive locus rrt.

93 us (TCV) depends on the resistance (R) gene, HRT, and the recessive locus rrt.

94 arbors the sequence-related resistance genes HRT and RCY1 in different ecotypes.

95 When fed synthetic groundwater at 11-3.6 h HRT, the upflow bioreactor removed >99.7% of the influen

96 e(-) equiv L(-1) d(-1) was achieved at 3.6 h HRT.

97 A total of 1276 eligible participants had HRT scans of both eyes.

98 However, HRT suppresses NotchICD/CBF-1 binding to the SMA promote

99 l compared with women who did not begin HRT, HRT seemed to be much more effective in controlling hot

100 rtional hazards models were used to identify HRT variables that predicted which participants in the E

101 Thus, if HRT is to be used in women with an intact uterus, this s

102 in, CA), the Heidelberg Retina Tomograph II (HRT II; Heidelberg Engineering, GmbH, Dossenheim, German

103 th a retinal tomograph (Retina Tomograph II [HRT]; Heidelberg Engineering, Heidelberg, Germany).

104 aging with Heidelberg Retinal Tomograph III (HRT-III) (Heidelberg Engineering) CSLO within 6 months o

105 A portion of the difference in HRT and SD-OCT disc measurements is due to HRT's magnifi

106 logy of hormone receptor-positive disease in HRT users differs from that in nonusers.

107 Resistance to TCV and HRT gene expression in HRT act1 plants was inducible by SA but not by glycerol,

108 sphate dehydrogenase restored 18:1 levels in HRT ssi2 plants and reestablished a dependence on rrt.

109 n-positive hippocampal cells was observed in HRT rats that ran voluntarily on a running wheel, wherea

110 not activate this 18:1-regulated pathway in HRT plants, but instead resulted in the induction of sev

111 -light relieves this repression resulting in HRT degradation.

112 e by SA but not by glycerol, whereas that in HRT pad4 plants was inducible by glycerol but not by SA.

113 ne acetate (NETA), another progestin used in HRT, acts like an estrogen at high doses, upregulating e

114 with severe glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx

115 tance in RRT-containing plants by increasing HRT transcript levels in a PAD4-dependent manner.

116 menopausal women, ever using HRT, increasing HRT duration of use in quartiles, and increasing quartil

117 duction of oleic acid (18:1) can also induce HRT gene expression and confer resistance to TCV.

118 tolic filling (enhanced lusitropy - lowering HRT), makes lymphatic contractions stronger (enhanced in

119 progestin (medroxyprogesterone acetate, MPA) HRT increases this risk.

120 re glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx would mi

121 Nevertheless, HRT is not currently used in the clinical practice.

122 g cancer for low dietary boron intake and no HRT use was 2.07 (95% CI: 1.53, 2.81).

123 was significantly higher in patients with no HRT compared with patients who received HRT (79 v 39 mon

124 Univariate and multivariate analyses of HRT parameters, SD-OCT circumpapillary retinal nerve fib

125 The benefits of HRT can be balanced against the risk for flare because H

126 est that the presence of P as a component of HRT results in poorer hearing abilities in aged women ta

127 prevents blue-light-dependent degradation of HRT, consequently these plants show resistance to TCV un

128 ulate the proteasome-mediated degradation of HRT, likely via COP1, and blue-light relieves this repre

129 The effect of HRT on interval breast cancer risk is not fully explaine

130 vated levels of free SA or the expression of HRT.

131 f meningioma in women without the history of HRT use was 366 in 100,000.

132 of glycerol, increased transcript levels of HRT as well as several other R genes.

133 A number of HRT rim area progression strategies has been proposed.

134 arliest of which are present at the onset of HRT-detected ONH surface height depression.

135 nd control (nonlasered) eyes at the onset of HRT-detected surface depression (follow-up 1; [FU1]) and

136 Overexpression of HRT can compensate for the absence of PHOT2 but not CRY2

137 showed susceptibility, but overexpression of HRT coupled with high levels of endogenous SA resulted i

138 f disease severity, repeatability results of HRT-II were better than those of StratusOCT.

139 Further studies examining the role of HRT use on outcomes from lung cancer, especially in wome

140 y boron may have actions similar to those of HRT; however, no previous study has reported the associa

141 he definitions of menopause and prior use of HRT as applied by the WHI investigators to the two popul

142 Since 1991, use of HRT has resulted in some 1300 additional ovarian cancers

143 elative risk for current versus never use of HRT was greater for serous than for mucinous, endometroi

144 moderate/severe periodontitis among users of HRT versus participants who did not use HRT was 0.69 amo

145 ovarian cancer in current and never users of HRT were 2.6 (2.4-2.9) and 2.2 (2.1-2.3) per 1000, respe

146 Past users of HRT were not at an increased risk of ovarian cancer (0.9

147 For current users of HRT, incidence of ovarian cancer increased with increasi

148 Among ever-users of HRT, recurrence risk was two-fold lower for estrogen rec

149 Among never-users of HRT, the expected beneficial effect of ER- or PR-positiv

150 gative tumors; whereas, among never-users of HRT, there was no statistically significant association

151 and meta-analysis of the predictive value of HRT for the end points of total mortality, CD, and fatal

152 s modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99).

153 form a complex in the presence or absence of HRTs.

154 Information on HRT use was obtained at recruitment and updated where po

155 ions in Glaucoma Study (DIGS) were tested on HRT II, StratusOCT, GDx VCC, and standard automated peri

156 CA), confocal scanning laser ophthalmoscopy (HRT II; Heidelberg Engineering, Heidelberg, Germany), an

157 imaging with Scanning Laser Ophthalmoscopy (HRT), Scanning Laser Polarimetry (GDx) and Optical Coher

158 phs, confocal scanning laser ophthalmoscopy (HRT-3; Heidelberg Engineering, Heidelberg, Germany), and

159 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced a

160 ged 65 years or more, odds ratios for HBC or HRT use were around the null.

161 n the dark, transgenic plants overexpressing HRT showed susceptibility, but overexpression of HRT cou

162 sis of meningioma and either current or past HRT use in women.

163 ingioma in women with either current or past HRT use was 865 in 100,000, whereas the frequency of men

164 documented history of either current or past HRT use.

165 56 (11%) of whom were either current or past HRT users.

166 ,037 (5%) were documented as current or past HRT users.

167 In postacute myocardial infarction patients, HRT had pooled risk ratios of 3.53 (95% confidence inter

168 usal or who consistently take postmenopausal HRT.

169 for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy,

170 1001 of 3519 women (28.4%) without previous HRT use (odds ratio [OR] 1.72 [95% CI 1.53-1.93]).

171 reast cancer, but estrogen and progesterone (HRT) did.

172 required for the stability of the R protein HRT, and thereby resistance to Turnip Crinkle virus (TCV

173 fied as "low responders" to the Allerport(R) HRT (%HR due to anti-IgE below 20%) were excluded.

174 d 51 subjects who underwent the Allerport(R) HRT before an oral food challenge (OFC) consisting of he

175 to evaluate the utility of the Allerport(R) HRT in the diagnosis of hen's egg allergy.

176 Conclusion Allerport(R) HRT is useful for the diagnosis of hen's egg allergy, an

177 We examined whether the Allerport(R) HRT was useful as a means of diagnosing hen's egg allerg

178 h no HRT compared with patients who received HRT (79 v 39 months, respectively; hazard ratio = 1.97;

179 normal tissues of several patients receiving HRT.

180 increased stroke severity in women receiving HRT or estrogen alone.

181 s observed in postmenopausal women receiving HRT.

182 iry enhancer of split (HES) and HES-related (HRT) genes, they are known to crosstalk with other signa

183 When they last reported HRT use, 287,143 women (30%) were current users and 186

184 rements of optic disc damage for OCT (RNFL), HRT (mean height contour), and GDx (RNFL) were r = 0.90

185 he inverse association remained significant (HRT OR = 0.45, 95% CI 0.30-0.66, P < 0.0001; BCP OR = 0.

186 with increased commission errors and slower HRT, adjusting for child IQ, age, sex, blood lead level,

187 or revision of the HRT operational software (HRT-3), HRT's ability to correctly classify glaucomatous

188 associated with use and duration of specific HRT formulations were calculated for total incident lung

189 ced fewer hot flushes than women who stopped HRT (22.9% v 34.3%, respectively; P = .03).

190 e first 6 months than those who did not take HRT (60.8% v 49.2%, respectively; P = .09).

191 omen (86%), whereas 86 women (17%) had taken HRT.

192 an older age at menopause, and never taking HRT, both in cases and controls.

193 In contrast, women on placebo taking HRT at entry experienced fewer hot flushes than women wh

194 In the tamoxifen arm, more women taking HRT at entry experienced hot flushes in the first 6 mont

195 The data suggest that women taking HRT comprising an estrogen plus MPA may have an increase

196 lts of observational studies in women taking HRT rely on self-reporting of gastro-oesophageal symptom

197 oorer hearing abilities in aged women taking HRT, affecting both the peripheral (ear) and central (br

198 lities among 124 postmenopausal women taking HRT, treated with estrogen and progestin (E+P; n = 32),

199 with the best parameter from each technique: HRT-II global cup-to-disc area ratio (0.861, 75.95%); GD

200 T (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-pl

201 al cycle changes, while menopause, long-term HRT, and presence of milk in lactating women affected th

202 Short-term HRT use does not negate the protective effect of BPO on

203 noprecipitation experiments demonstrate that HRT does not disrupt the association of NotchICD and CBF

204 Here we show that HRT-mediated HR and resistance are dependent on light.

205 We have previously shown that HRT-mediated resistance to TCV is dependent on SA-mediat

206 umber of prior animal studies suggested that HRT may be neuroprotective and cardioprotective.

207 The HRT GPS sensitivity was 81.5% (95% CI, 73.9%-87.6%), and

208 The HRT is a promising tool for monitoring patients with, or

209 The HRT MRA had the highest sensitivity (87.0%; 95% confiden

210 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an e

211 type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01).

212 The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group.

213 For the HRT II parameter Moorfields regression analysis classifi

214 ds regression analysis (MRA) result from the HRT was used as a separate diagnostic classification.

215 rmany) glaucoma probability score (GPS), the HRT Moorfields regression analysis (MRA), scanning laser

216 There were 489 participants in the HRT Ancillary Study to the EGPS.

217 In the HRT group, there were 1 death, 1 stroke, 2 cases of deep

218 ch signaling mediated through members of the HRT family of basic helix-loop-helix transcription facto

219 ed resistance to TCV via upregulation of the HRT gene.

220 elopments in the third major revision of the HRT operational software (HRT-3), HRT's ability to corre

221 milar issues were observed when reducing the HRT to 2 days, indicating that temperature<60 degrees C

222 With reference to the HRT TCA and OCT GPA, ONH surface depression occurred bef

223 When the HRT MRA was used as the diagnostic standard, sensitiviti

224 with exogenous hormone replacement therapy (HRT) are currently unknown.

225 a on the use of hormone replacement therapy (HRT) as a possible risk factor for meningioma.

226 40.6%) who used hormone replacement therapy (HRT) before trial entry developed joint symptoms compare

227 nsistently took hormone replacement therapy (HRT) between menopause and bone lead measurement (n = 14

228 jor debate when hormone replacement therapy (HRT) did not reduce coronary heart disease in postmenopa

229 Sex and hormone replacement therapy (HRT) effects on the distribution of glucose tolerance we

230 were receiving hormone replacement therapy (HRT) for alleviation of menopausal symptoms.

231 ity, and use of hormone replacement therapy (HRT) in a retrospective analysis.

232 The role of hormone replacement therapy (HRT) in lung cancer development is unclear.

233 Hormone replacement therapy (HRT) increases the risk of developing breast, ovarian, a

234 Hormone replacement therapy (HRT) is frequently prescribed to postmenopausal women, b

235 Hormone replacement therapy (HRT) is widely used to manage menopausal symptoms in wom

236 Hormone replacement therapy (HRT) may reduce lung cancer risk.

237 ive history and hormone replacement therapy (HRT) or birth control pills (BCPs) influence risk for ag

238 the effects of hormone replacement therapy (HRT) use and smoking.

239 raction between hormone replacement therapy (HRT) use and tumor hormone receptor status on risk of re

240 sed duration of hormone replacement therapy (HRT) use in quartiles was associated with decreased risk

241 postmenopausal hormone replacement therapy (HRT) use.

242 le consumption, hormone-replacement therapy (HRT), and estrogen exposure on the basis of menopausal s

243 tions regarding hormone replacement therapy (HRT), and provided a blood sample for serum vitamin D as

244 ceptives and in hormone replacement therapy (HRT), both on their own and in combination with EE2.

245 clinical use of hormone replacement therapy (HRT), it is critical to understand HRT effects on sensor

246 ntrol (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively.

247 y components of hormone replacement therapy (HRT).

248 cial effects of hormone replacement therapy (HRT).

249 with the use of hormone replacement therapy (HRT).

250 current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38 to 2.44), and body mass inde

251 and diagnosis of meningioma, and therefore, HRT use may be a risk factor for meningioma.

252 rithmic associations between RNFL thickness (HRT II, StratusOCT, and GDx VCC) and neuroretinal rim ar

253 s, commission errors, and hit reaction time (HRT), with higher scores indicating increased errors or

254 nd systolic diameters, half-relaxation time (HRT), contraction frequency, ejection fraction and fract

255 At a combined hydraulic retention time (HRT) for both processes of 9 h, the effluent tCOD was re

256 of pond depth and hydraulic retention time (HRT) in response to seasonal changes.

257 teady state with a hydraulic retention time (HRT) of 1 day was reached, the process achieved complete

258 demand (COD) at a hydraulic retention time (HRT) of 11 h and reduced about 50% suspended solids.

259 grees C) at short hydraulic retention times (HRT).

260 er within 24 h (3 hydraulic retention times (HRTs)) and resume removal near 95%.

261 e modulations in diffusion parameters due to HRT and lactation should be taken into account in DTI ev

262 n HRT and SD-OCT disc measurements is due to HRT's magnification correction algorithm.

263 cells, and this effect was also sensitive to HRT inhibition.

264 severity on the Heidelberg Retina Tomograph (HRT) Glaucoma Probability Score (GPS) and the Moorfields

265 photographs and Heidelberg Retina Tomograph (HRT) images were obtained during one visit, which was wi

266 on research on Heidelberg retina tomograph (HRT) imaging of the optic nerve head in glaucoma.

267 eyes) with >/=4 Heidelberg Retina Tomograph (HRT)-II exams from the Diagnostic Innovations in Glaucom

268 be 200x200) and Heidelberg Retina Tomograph (HRT).

269 etry (SAP) and Heidelberg Retinal Tomograph (HRT II) were both more sensitive than GAT (41, 95% CrI 1

270 maged by CSLO (Heidelberg Retinal Tomograph [HRT]; Heidelberg Engineering, GmbH, Dossenheim, Germany)

271 ophthalmoscopy (Heidelberg Retina Tomograph; HRT).

272 g the MMDT and Heidelberg Retina Tomography (HRT; Heidelberg Engineering, Heidelberg, Germany) scanni

273 gorithms: the Heidelberg Retinal Tomography (HRT; Heidelberg Engineering, Heidelberg, Germany) glauco

274 y parameters (Heidelberg Retinal Tomography [HRT]; Heidelberg Engineering, Heidelberg, Germany).

275 The traditional HRT low responders (n=27) were separated into two groups

276 nse trainer (LRT) and high-response trainer (HRT) adult male rats to various forms of physical exerci

277 enous levels of Hairy Related Transcription (HRT) factor 2 (HRT2) peaked concurrently with inhibitory

278 Heart rate turbulence (HRT) has been proposed as a candidate marker of altered

279 ght induces degradation of CRY2, and in turn HRT, resulting in susceptibility.

280 therapy (HRT), it is critical to understand HRT effects on sensory systems.

281 s of HRT versus participants who did not use HRT was 0.69 among participants who were vitamin D suffi

282 women who consumed low boron and did not use HRT were at substantial increased odds.

283 Women who use HRT are at an increased risk of both incident and fatal

284 Because millions of women use HRT, it is important to consider how the WHI and other r

285 re years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95% confidence interval

286 teers and postmenopausal volunteers who used HRT (P = .31-0.93).

287 omen with high dietary boron intake who used HRT, the odds ratio for lung cancer for low dietary boro

288 Among postmenopausal women, ever using HRT, increasing HRT duration of use in quartiles, and in

289 t-retest variability of ONH topography using HRT-II and StratusOCT increased with increasing disease

290 The diagnostic performances of the GDx VCC, HRT II, and Stratus OCT were significantly influenced by

291 ractions were examined, to determine whether HRT or BCP modifies the effect of established genetic ri

292 All pair-wise HRT-genotype and BCP-genotype interactions were examined

293 Risks associated with HRT varied significantly according to tumour histology (

294 ct and was in better agreement than CAP with HRT-determined rim area.

295 gnificantly stronger using OCT compared with HRT.

296 hout HRT use as compared with the group with HRT use (P < .01) and premenopausal volunteers (P < .01)

297 D) and whether genetic factors interact with HRT to modulate AMD risk.

298 vidence suggesting that ARMS2 interacts with HRT to modulate AMD risk and are consistent with previou

299 ce to Topographic Change Analysis (TCA) with HRT and Guided Progression Analysis (GPA) with Cirrus HD

300 , and optic nerve head (ONH) topography with HRT-II (retinal tomograph; Heidelberg Engineering GmbH,

301 significantly lower (a) in the group without HRT use as compared with the group with HRT use (P < .01